Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer

• Main Authors: Dennis J. Slamon, Richard S. Finn, Gottfried E. Konecny, Michael J. Haykinson, Nuraly K. Avliyakulov, Ondrej Kalous, Erika M. von Euw, Lee Anderson, Marlena S. Fejzo
• Format: Article
• Language: English
• Published: MDPI AG 2013-02-01
• Series: International Journal of Molecular Sciences
• Subjects: ADRM1; oncogene; ovarian cancer
• Online Access: http://www.mdpi.com/1422-0067/14/2/3094

Approximately 25,000 ovarian cancers are diagnosed in the U.S. annually, and 75% are in the advanced stage and largely incurable. There is critical need for early detection tools and novel treatments. Proteasomal ubiquitin receptor ADRM1 is a protein that is encoded by the ADRM1 gene. Recently, we showed that among 20q13-amplified genes in ovarian cancer, ADRM1 overexpression was the most highly correlated with amplification and was significantly upregulated with respect to stage, recurrence, and metastasis. Its overexpression correlated significantly with shorter time to recurrence and overall survival. Array-CGH and microarray expression of ovarian cancer cell lines provided evidence consistent with primary tumor data that ADRM1 is a 20q13 amplification target. Herein, we confirm the ADRM1 amplicon in a second ovarian cancer cohort and define a minimally amplified region of 262 KB encompassing seven genes. Additionally, using RNAi knock-down of ADRM1 in naturally amplified cell line OAW42 and overexpression of ADRM1 via transfection in ES2, we show that (1) ADRM1 overexpression increases proliferation, migration, and growth in soft agar, and (2) knock-down of ADRM1 results in apoptosis. Proteomic analysis of cells with ADRM1 knock-down reveals dysregulation of proteins including CDK-activating kinase assembly factor MAT1. Taken together, the results indicate that amplified ADRM1 is involved in cell proliferation, migration and survival in ovarian cancer cells, supporting a role as an oncogene and novel therapeutic target for ovarian cancer.